LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations
Titel:
LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations
Auteur:
Schuler, Martin Yang, James Chih-Hsin Yamamoto, Nobuyuki O’Byrne, Ken Hirsh, Vera Mok, Tony Massey, Dan Zazulina, Victoria Shahidi, Mehdi Sequist, Lecia